Ray Dalio Bristol Myers Squibb CO Transaction History

Bridgewater Associates, LP

$23.8 Billion
Q3 2025

A detailed history of Ray Dalio (Bridgewater Associates, LP) transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Bridgewater Associates, LP holds 444,032 shares of BMY stock, worth $20.8 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

444,032

Previous 2,703,724 83.58%

Holding current value

$20.8 Million

Previous $125 Million 84.0%

% of portfolio

0.08%

Previous 0.54%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$43.31 - $48.98 $97.9 Million - $111 Million	-2,259,692 Reduced 83.58%	444,032 $20 Million
Q2 2025 Aug 13, 2025	BUY	$44.12 - $59.6 $16 Million - $21.6 Million	362,486 Added 15.48%	2,703,724 $125 Million
Q1 2025 May 14, 2025	BUY	$53.9 - $63.11 $15.1 Million - $17.7 Million	280,162 Added 13.59%	2,341,238 $143 Million
Q4 2024 Feb 13, 2025	BUY	$51.92 - $59.94 $75.3 Million - $87 Million	1,450,718 Added 237.68%	2,061,076 $117 Million
Q3 2024 Nov 13, 2024	BUY	$39.66 - $51.75 $2.2 Million - $2.87 Million	55,364 Added 9.98%	610,358 $31.6 Million
Q2 2024 Aug 14, 2024	SELL	$40.25 - $52.99 $5.97 Million - $7.85 Million	-148,232 Reduced 21.08%	554,994 $23 Million
Q1 2024 May 14, 2024	SELL	$47.98 - $54.4 $95,048 - $107,766	-1,981 Reduced 0.28%	703,226 $38.1 Million
Q4 2023 Feb 14, 2024	SELL	$48.48 - $57.85 $32.9 Million - $39.2 Million	-678,275 Reduced 49.03%	705,207 $36.2 Million
Q3 2023 Nov 13, 2023	BUY	$57.89 - $64.73 $15.1 Million - $16.9 Million	261,063 Added 23.26%	1,383,482 $80.3 Million
Q2 2023 Aug 11, 2023	BUY	$63.71 - $70.74 $30.6 Million - $34 Million	481,035 Added 75.0%	1,122,419 $71.8 Million
Q1 2023 May 12, 2023	SELL	$65.71 - $74.53 $16.3 Million - $18.5 Million	-247,947 Reduced 27.88%	641,384 $44.5 Million
Q4 2022 Feb 13, 2023	SELL	$68.48 - $81.09 $944,339 - $1.12 Million	-13,790 Reduced 1.53%	889,331 $64 Million
Q3 2022 Nov 10, 2022	BUY	$0.13 - $76.84 $18,734 - $11.1 Million	144,114 Added 18.99%	903,121 $64.2 Million
Q2 2022 Aug 11, 2022	SELL	$72.62 - $79.98 $2.45 Million - $2.7 Million	-33,729 Reduced 4.25%	759,007 $58.4 Million
Q1 2022 May 13, 2022	BUY	$61.48 - $73.72 $29.3 Million - $35.2 Million	477,281 Added 151.3%	792,736 $57.9 Million
Q4 2021 Feb 14, 2022	BUY	$53.63 - $62.52 $5.92 Million - $6.9 Million	110,359 Added 53.81%	315,455 $19.7 Million
Q3 2021 Nov 12, 2021	BUY	$59.17 - $69.31 $7.39 Million - $8.66 Million	124,879 Added 155.68%	205,096 $12.1 Million
Q2 2021 Aug 13, 2021	BUY	$61.91 - $67.42 $4.63 Million - $5.05 Million	74,848 Added 1394.08%	80,217 $5.36 Million
Q1 2021 May 14, 2021	BUY	$59.34 - $66.74 $318,596 - $358,327	5,369 New	5,369 $339,000
Q2 2020 Aug 12, 2020	SELL	$54.82 - $64.09 $3.79 Million - $4.43 Million	-69,134 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$46.4 - $67.43 $3.21 Million - $4.66 Million	69,134 New	69,134 $3.85 Million
Q4 2019 Feb 13, 2020	SELL	$49.21 - $64.19 $10.8 Million - $14.1 Million	-219,568 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$42.77 - $50.71 $9.39 Million - $11.1 Million	219,568 New	219,568 $11.1 Million
Q2 2019 Aug 13, 2019	SELL	$44.62 - $49.34 $44.1 Million - $48.8 Million	-989,293 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$45.12 - $53.8 $19.6 Million - $23.3 Million	433,770 Added 78.08%	989,293 $47.2 Million
Q4 2018 Feb 13, 2019	BUY	$48.76 - $63.23 $14.6 Million - $18.9 Million	298,453 Added 116.1%	555,523 $28.9 Million
Q3 2018 Nov 13, 2018	SELL	$55.19 - $62.25 $914,167 - $1.03 Million	-16,564 Reduced 6.05%	257,070 $16 Million
Q2 2018 Aug 13, 2018	BUY	$50.53 - $62.98 $13.8 Million - $17.2 Million	273,634 New	273,634 $0

Others Institutions Holding BMY

# of Institutions

2,679

Shares Held

1.58B

Call Options Held

28.2M

Put Options Held

28.4M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $99.5B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track Ray Dalio's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgewater Associates, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bridgewater Associates, LP and Ray Dalio with notifications on news.

Account